Molecular Templates

Molecular Templates logo
🇺🇸United States
Ownership
Public
Established
2000-01-01
Employees
62
Market Cap
-
Website
http://www.mtem.com
Introduction

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and...

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

First Posted Date
2023-09-13
Last Posted Date
2024-11-01
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
15
Registration Number
NCT06034860
Locations
🇺🇸

The Angeles Clinic, Los Angeles, California, United States

🇺🇸

Horizon Oncology Research, LLC, Lafayette, Indiana, United States

🇺🇸

Washington University in St. Louis, Saint Louis, Missouri, United States

and more 2 locations

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

First Posted Date
2021-03-12
Last Posted Date
2024-11-04
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
64
Registration Number
NCT04795713
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

USC Medical Center, Los Angeles, California, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

and more 13 locations

Study of MT-5111 in HER2-positive Solid Tumors

First Posted Date
2019-07-23
Last Posted Date
2023-06-18
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
50
Registration Number
NCT04029922
Locations
🇺🇸

UCLA Hematology & Oncology, Santa Monica, California, United States

🇺🇸

BRCR Medical Center, Plantation, Florida, United States

🇦🇺

Cancer Research South Australia, Adelaide, South Australia, Australia

and more 25 locations

A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2019-07-12
Last Posted Date
2024-01-17
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
14
Registration Number
NCT04017130
Locations
🇺🇸

The Ohio State University, Columbus, Ohio, United States

🇺🇸

Vanderbilt University Medical Center- Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Miami University, Miami, Florida, United States

and more 4 locations

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2018-08-24
Last Posted Date
2022-08-16
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
9
Registration Number
NCT03645395
Locations
🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

🇺🇸

Boca Raton Clinical Research, Plantation, Florida, United States

and more 2 locations

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

First Posted Date
2018-04-04
Last Posted Date
2022-08-16
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
8
Registration Number
NCT03488251
Locations
🇺🇸

UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

🇺🇸

Good Samaritan Hospital, Cincinnati, Ohio, United States

and more 6 locations

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

First Posted Date
2016-03-22
Last Posted Date
2019-10-11
Lead Sponsor
Molecular Templates, Inc.
Registration Number
NCT02715843
Locations
🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

First Posted Date
2015-02-11
Last Posted Date
2022-08-18
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
38
Registration Number
NCT02361346
Locations
🇺🇸

BRCR Medical Center, Plantation, Florida, United States

🇨🇦

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

and more 37 locations
© Copyright 2024. All Rights Reserved by MedPath